Ashling Wahner

Associate Editor, OncLive

Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

Blinatumomab May Be an Effective Alternative to Consolidation Chemotherapy in Down Syndrome B-ALL

September 3rd 2024

Sujith Samarasinghe, BSc, MBBS, MRCPCH, FRCPath, PhD, discusses the use of blinatumomab in children with Down syndrome acute lymphoblastic leukemia.

Azer-Cel Produces CRs in R/R DLBCL After Prior Autologous CAR T-Cell Therapy

September 3rd 2024

Azercabtagene zapreleucel produced complete responses in relapsed/refractory diffuse large B-cell lymphoma after prior autologous CAR T-cell therapy.

FDA Awards Fast Track Designation to CB-012 in Relapsed/Refractory AML

September 3rd 2024

The FDA has granted fast track designation to the allogeneic CAR T-cell therapy CB-012 for relapsed/refractory acute myeloid leukemia.

MT-302 Under Investigation in Advanced or Metastatic Epithelial Tumors

September 3rd 2024

Charlotte Lemech, MBBS, discusses the mechanism of action of MT-302, as well as the aims of the MYE Symphony trial and its potential future implications.

Salgia Summarizes the Benefits of Tepotinib in MET Exon 14–Mutated NSCLC

September 2nd 2024

Dr Salgia discusses how he chooses between tepotinib and capmatinib in patients with stage IV NSCLC harboring MET exon 14 skipping mutations.

Growth in the Multiple Myeloma Treatment Armamentarium Diversifies Treatment Strategies

September 2nd 2024

Rahul Banerjee MD, FACP, discusses how he decides between treatment approaches across subsets of patients with multiple myeloma.

Abemaciclib Monotherapy Elicits No Response in Advanced RCC: Where the Field is Headed From Here

August 30th 2024

Bradley McGregor, MD, discusses how abemaciclib monotherapy did not elicit clinically meaningful activity in heavily pretreated metastatic clear cell RCC.

Dr Chase on the FDA Approval of Dostarlimab Plus Chemotherapy in Endometrial Cancer

August 30th 2024

Dana M. Chase, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with primary advanced or recurrent endometrial cancer.

Dr McCarthy on Neutrophil Activity in Multiple Myeloma

August 30th 2024

Philip McCarthy, MD, discusses a study of neutrophil gene signatures within focal lesions that are linked to progression-free survival in multiple myeloma.

Revisit Every OncLive On Air Episode From August 2024

August 30th 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in August 2024.

Chiang Contextualizes the Optimal Use of Lurbinectedin in SCLC Management

August 29th 2024

Dr Chiang discusses the use of lurbinectedin in small cell lung cancer and tips for managing toxicities associated with this agent.

Dr Li on Cretostimogene Grenadenorepvec Plus Pembrolizumab in BCG-Unresponsive NMIBC

August 29th 2024

Roger Li, MD, discusses the final analysis of the CORE-001 trial of cretostimogene grenadenorepvec plus pembrolizumab in BCG-unresponsive NMIBC with CIS.

Dr Tolaney on Standard Frontline Treatment Approaches in HER2+ Breast Cancer

August 29th 2024

Sara M. Tolaney, MD, MPH, discusses standard-of-care frontline treatment approaches for patients with HER2-positive breast cancer.

TP53 Mutations Have Strong Prognostic Value for PFS and OS Outcomes in CLL

August 29th 2024

Consuelo Bertossi, MD, discusses research elucidating the role and prognostic significance of TP53 mutations in chronic lymphocytic leukemia.

ADT Plus Darolutamide Is Associated With Lower Rates of PSA Progression in nmCRPC

August 29th 2024

Alicia Morgans, MD, MPH, discusses the use of ADT in combination with darolutamide or placebo in nonmetastatic castration-resistant prostate cancer.

Shortened Trastuzumab Administration Does Not Improve DFS in ERBB2+ Breast Cancer

August 29th 2024

Adjuvant trastuzumab plus concurrent chemotherapy led to inferior DFS outcomes when administered for 9 weeks vs 1 year in ERBB2-positive breast cancer.

Charlson Comorbidities Associated With Lower Likelihood of CR in Epithelial Ovarian Cancer

August 28th 2024

Kimberly Cannavale, MPH, discusses a study of the association between Charlson comorbidity index and complete remission in patients with ovarian cancer.

Novel Targets Facilitate Treatment Advances and Spur Further Questions in Endometrial Cancer

August 28th 2024

Ritu Salani, MD, discusses the development of ADCs, the potential role of selinexor, and the use of PARP inhibitors across endometrial cancer subsets.

NDA Submitted to FDA for TLX101-CDx in Progressive/Recurrent Glioma

August 28th 2024

An NDA has been submitted to the FDA for TLX101-CDx for the characterization of progressive or recurrent glioma in adult and pediatric patients.

Enfortumab Vedotin Plus Pembrolizumab Approved in Europe for Metastatic Urothelial Cancer

August 28th 2024

The European Commission granted marketing authorization to frontline enfortumab vedotin plus pembrolizumab for unresectable/metastatic urothelial cancer.